Compare Apartment Investment and Management Co (AIV) vs Amgen, Inc. (AMGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apartment Investment and Management Co vs Amgen, Inc. — how do they compare? Apartment Investment and Management Co trades at $2.84 (market cap $422.94M), while Amgen, Inc. trades at $367.99 (market cap $198.67B). The key difference: Amgen, Inc. is far larger — about 469.7× Apartment Investment and Management Co's market cap, and Amgen, Inc. pays a 2.74% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.
| AIV | AMGN | |
|---|---|---|
Market Cap | $422.94M | $198.67B |
Sector | Real Estate | Health |
52-Week High | $8.76 | $388.16 |
52-Week Low | $2.87 | $271.18 |
Enterprise Value | $669.06M | $243.95B |
Dividend Yield | — | 2.74% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
